Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis ...

In this article, we are going to take a look at where Alumis Inc. (NASDAQ:ALMS) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on Thursday ...

The latest price target for Alumis (NASDAQ:ALMS) was reported by Oppenheimer on May 15, 2025. The analyst firm set a price target for $25.00 expecting ALMS to rise to within 12 months (a possible ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Alumis Inc. (ALMS – Research Report) today and set a price target of $14.00. The company’s shares closed yes ...

Today we look at two noteworthy recent insider buys. On Monday, Alumis', Srinivas Akkaraju, made a $1.48M purchase of ALMS, buying 320,290 shares at a cost of $4.61 each. Alumis is trading up ...

It's estimated that tens of thousands converge on this port megacity during Ramadan to collect alms. Faisal Edhi, chairman of the Edhi Foundation, Pakistan's best-known charity organization ...

But we, the people, are also responsible. We give alms to these actors without thinking twice when instead, we should be looking around in search of those who are actually needy but never ask for ...